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ABSTRACT
Racemic Gossypol [(±)-GOS], composed of both ()-GOS and (þ)-GOS, is a small BH3-mimetic
polyphenol derived from cotton seeds. (±)-GOS has been employed and well tolerated by cancer
patients. Head and neck carcinoma (HNC) represents one of the most fatal cancers worldwide,
and a significant proportion of HNC expresses high levels of antiapoptotic Bcl-2 proteins. In this
study, we demonstrate that (±)-GOS inhibits cell proliferation and induces apoptosis and autoph-
agy of human pharynx, tongue, and salivary gland cancer cell lines and of mouse salivary gland
cancer cells (SALTO). (±)-GOS was able to: (a) decrease the ErbB2 protein expression; (b) inhibit
the phosphorylation of ERK1/2 and AKT; (c) stimulate p38 and JNK1/2 protein phosphorylation.
(±)-GOS administration was safe in BALB/c mice and it reduced the growth of transplanted
SALTO cells in vivo and prolonged mice median survival. Our results suggest the potential role of
(±)-GOS as an antitumor agent in HNC patients.
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Introduction
Head and neck carcinoma (HNC) represents the sev-
enth most common cancer worldwide, and it mainly
involves the larynx, pharynx, oral cavity, and tongue
(Ferlay et al. 2015). A significant proportion of head
and neck tumors expresses high levels of the antiapop-
totic Bcl-2 proteins, which correlates directly with
resistance to chemo- and radio-therapy and is associ-
ated with the poor clinical outcomes in HNC patients
(Xie et al. 1999; Yu et al. 2003; Andrews et al. 2004).
The Bcl-2 family proteins (Bcl-2, Bcl-xL, Bcl-W, MCL-
1, A1/BFL-1) have a structural homology in the Bcl-
2 homology (BH) 1, 2, 3, and 4 domains. These
proteins can interact with BH3 proteins, such as Bax
or Beclin-1, and regulate different intracellular path-
ways, including apoptosis and autophagy (Maiuri
et al. 2007; Sinha & Levine 2008; Vela et al. 2013).
The antiapoptotic protein Bcl-2 binds directly the
proapoptotic protein Bax and blocks the activation
of the apoptotic pathway. When the ratio between
Bax and Bcl-2 increases, there is an increase of the
mitochondrial outer membrane permeabilization and
the cytosol cytochrome c release and caspase 3 acti-
vation (Hata et al. 2015). Autophagy is a type II
programmed cell death which activates the lysosomal
degradation pathway and is essential for cellular
homeostasis. Beclin-1 plays an essential role in
autophagy by interacting with different cofactors to
form a Beclin-1-Vps 34-Vps 35 core complex
(Marquez & Liang 2012). Furthermore, Beclin-1 has
a BH3 domain at the N-terminus which makes pos-
sible its interaction with Bcl-2 which is then inacti-
vated. Beclin-1 dysfunction or increased levels of
Bcl-2 can block Beclin-1-dependent autophagy thus
contributing to cancer progression (Kang et al.
2011). To overcome these mechanisms, a new class
of compounds, called “BH3-mimetics”, has been
developed. The BH3-mimetics can directly activate
apoptosis and autophagy by binding and inhibiting
Bcl-2/Bcl-xL (Delbridge & Strasser 2015).
Racemic Gossypol ((±)-GOS; (±)-2,20-bis(8-Formyl-
1,6,7-trihydroxy-5-isopropyl-3-methylnaphthalene),
composed of both ()-GOS and (þ)-GOS, is a natur-
ally occurring polyphenolic yellow pigment present in
cotton-seeds and cotton plants-derived products, used
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in herbal medicines in China (Huang et al. 2006).
Cotton is produced worldwide and its major products
are cotton fibers, cotton-seed oil, and cotton-seed pro-
teins. Gossypol is the principal component of the pig-
ment glands, mainly found not only in cotton-seeds
but also in bark of plant roots, leaves, seed hulls, and
flowers. Gossypol constitutes 20–40% of the gland
weight and accounts for 0.4–1.7% of the whole kernel
of cotton-seeds. The amount of gossypol is dependent
from the species and variety of cotton plant, soil and
climatic conditions, water supply, agriculture techni-
ques, and composition of fertilizers used. Cotton-seed
oil and proteins are extracted from the cotton-seeds
gland as a by-product of cotton fibers production, and
the gossypol content in oil is influenced by the oilseed
processing (Wang et al. 2009). It is estimated that from
1 kg of fibers the plant produces about 1.65 kg of seeds,
which can be employed for the production of cotton-
seed oil and cotton-seed meal as food for human con-
sumption and animals feed (Sunilkumar et al. 2006).
However, food sources containing gossypol has limited
use because gossypol possesses anti-proliferative activ-
ity (Wang et al. 2009). Indeed, the US Food and Drug
Administration (FDA 1974) specifies limits of 450 ppm
of free-gossypol in cotton-seed protein products for
human use, and the Protein Advisory Group of the
United Nations Food and Agriculture and World
Health Organizations (FAO/WHO/UNICEF 1972) spe-
cify limits of 600 ppm of free gossypol and 12,000 ppm
of total gossypol in food products.
On the other hand, several studies have high-
lighted the antitumoral activity of gossypol purified
from cotton plant. Indeed, the in vitro and in vivo
anti-proliferative effect of gossypol in various types
of cancer, including breast, ovary, cervix, uterus,
adrenals, pancreas, colon, and head and neck, has
been demonstrated (Huang et al. 2006). Gossypol is
a small BH3-mimetic compound, which is able to
inhibit Bcl-2/Bcl-xL. Gossypol can block the inter-
action between Bcl-2/Bcl-xL and Beclin-1 or Bax,
thus inducing apoptosis and autophagy (Meng et al.
2008; Lian et al. 2010). Gossypol was also employed
in phase I/II clinical trials, as single agent and also
in combination with conventional therapies, for the
treatment of different types of cancer and it was well
tolerated (Stein et al. 1992; Flack et al. 1993; van
Poznak et al. 2001; Sonpavde et al. 2012; Schelman
et al. 2014).
A phase II study employing gossypol, in combin-
ation with docetaxel, for the treatment of head and
neck squamous cell carcinoma has recently been com-
pleted. However, combined therapy with docetaxel
and gossypol failed to provide an increase in clinical
benefit for these HNC patients (Swiecicki et al. 2016).
In our study, we explored the in vitro and in vivo
(±)-GOS antitumor activity in HNC. We demonstrate
that (±)-GOS inhibits cell proliferation and induces
apoptosis and autophagy of human pharynx (FaDu),
tongue (CAL-27), and salivary gland (A-253) cancer
cells and of mouse salivary gland cancer cells
(SALTO), which were established from salivary adeno-
carcinoma arising in BALB-neuT transgenic male
mice. (±)-GOS was able to: (a) decrease the ErbB2
protein expression; (b) inhibit the phosphorylation of
ERK1/2 and AKT; (c) stimulate p38 and JNK1/2 phos-
phorylation. We demonstrated that (±)-GOS adminis-
tration was safe in BALB/c mice and it reduced the
growth of mouse-transplanted SALTO cells and pro-
longed mice median survival.
Overall, our results suggest the potential role of the
BH3-mimetic compound (±)-GOS as an antitumor
agent in HNC patients.
Materials and methods
Reagents
DMSO, (±)-Gossypol (GOS), and Sulforhodamine B
(SRB) were purchased from Sigma Aldrich (Milano,
Italy). Antibodies against AKT, phospho-AKT, Bax,
Bcl-2, JNK/SAPK1, JNK/SAPK (pT183/pY185), p38a/
SAPK2a, p38 MAPK (pT180/pY182) were obtained
from BD Pharmingen (BD Biosciences, San Jose, CA).
Antibodies against ERK1/2 (C-14), phospho-ERK (E-
4), PARP-1, and p53 (DO-1) were obtained from
Santa Cruz Biotechnology (Dallas, TX). Antibody
against LC3 was obtained from Novus Biologicals
(Littleton, CO). Antibodies against Beclin-1 were
obtained from Abcam (Cambridge, UK). The anti-cas-
pase 9 (C9), anti-caspase 8 (1C12), and anti-cleaved
caspase 3 (Asp175) antibodies were purchased from
Cell Signaling Technology (Danvers, MA). Anti-ErbB2
and anti-EGFR antisera were provided by Dr. M.H.
Kraus (University of Alabama, Birmingham, AL).
Rabbit polyclonal anti-Actin was obtained from
Sigma-Aldrich. Goat anti-mouse or anti-rabbit IgG
peroxidase-conjugated secondary antibodies were pur-
chased from Sigma-Aldrich.
Cell lines and treatments
Cell lines derived from carcinoma of the tongue
(CAL-27) or pharynx (FaDu) or salivary gland (A-
253) were maintained in RPMI containing 10% fetal
bovine serum, 100U/ml penicillin, and 100 lg/ml
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streptomycin. For treatments, cells were incubated
for the indicated times in the presence of GOS
(dose range 1.25–80 lM) or vehicle control
(DMSO0.1%). Neu-overexpressing salivary gland
cancer cells (H-2d) (SALTO) were kindly provided
by Prof. F. Cavallo (University of Torino) and Prof.
P.L. Lollini and Prof. P. Nanni (University of
Bologna) and maintained in DMEM containing 20%
fetal bovine serum, 100U/ml penicillin, and
100 lg/ml streptomycin. SALTO cells were estab-
lished from salivary gland adenocarcinoma arising in
BALB-neuT transgenic male mice hemizygous for
p53172R-H transgene driven by the whey acidic pro-
tein promoter (Pannellini et al. 2006).
Sulforhodamine B (SRB) assay
Cells were seeded at 5 103/well in 96-well plates and
incubated at 37 C to allow cell attachment. After 24 h,
the medium was changed, and the cells were treated
with GOS or DMSO and incubated for 24, 48, and
72 h, at concentrations of 1.25–80lM. The cells were
then fixed with cold trichloroacetic acid (final concen-
tration 10%) for 1 h at 4 C. After four washes with
distilled water, the plates were air-dried and stained
for 30min with 0.4% (wt/vol) SRB in 1% acetic acid.
After four washes with 1% acetic acid to remove the
unbound dye, the plates were air-dried, and cell-
bound SRB was dissolved with 200ll/well of 10-mM
unbuffered Tris base solution. The optical density
(O.D.) of the samples was determined at 540 nm with
a spectrophotometric plate reader. The percentage sur-
vival of the cultures treated with GOS was calculated
by normalizing their O.D. values to those of control
cultures treated with DMSO (Masuelli et al. 2014a).
The experiments were performed in triplicate and
repeated three times.
FACS analysis
Asynchronized, log-phase growing cells (60% conflu-
ent, approximately 2.5 105/well in 6-well plates)
were treated with GOS or DMSO in complete culture
medium. After 48 h, adherent as well as suspended
cells were harvested, centrifuged at 1500 rpm for
10min and washed twice with cold phosphate-buf-
fered saline (PBS). The cell pellets were resuspended
in 70% ethanol and incubated for 1 h at 20 C. The
cells were then washed twice with cold PBS, centri-
fuged at 1500 rpm for 10min, incubated for 1 h in the
dark with propidium iodide (25 lg/ml final concentra-
tion in 0.1% citrate and 0.1% Triton X-100), and ana-
lyzed by flow cytometry using a FACSCalibur
cytometer with CellQuest Pro 5.2 software (BD
Biosciences, San Jose, CA) (Masuelli et al. 2012a).
Preparation of cell lysates and Western blotting
Approximately 1 106 cells were seeded in 100-mm
tissue culture dishes 24 h prior to the addition of
20 lM GOS or vehicle control. After 24 h (for FaDu,
CAL-27, and A-253) and 48 h (for SALTO) of incuba-
tion, the cells were harvested, washed twice with cold
PBS, and lysed in RIPA lysis buffer (Triton X-100 1%,
SDS 0.1%, NaCl 200mM, Tris HCl 50mM pH 7.5,
PMSF 1mM, and NaOV 1mM) (Benvenuto et al.
2015; Frajese et al. 2016). After 30min at 4 C, the
mixtures were centrifuged at 12,000 g for 15min, and
the supernatants were analyzed by Western blotting.
For immunoblotting analysis, 50 lg of cell lysates were
resolved in 10% SDS-PAGE and then transferred to
nitrocellulose membranes. After blocking, the mem-
branes were incubated with specific primary antibodies
at 1–2 lg/ml concentrations overnight at 4 C. After
being washed, the filters were incubated with goat
anti-mouse or anti-rabbit IgG, peroxidase-conjugated
antibodies and developed by chemiluminescence as
previously described (Masuelli et al. 2012b). A densi-
tometric analysis of autoradiographic bands was per-
formed with ImageJ 1.42q software (National
Institutes of Health, Bethesda, MD) after blot
scanning.
Transmission electron microscopy
Ultrastructural analyses were performed on CAL-27
cells treated with 10 lM GOS or with DMSO for 24 h.
After treatment, the cells were fixed in 2.5% glutaral-
dehyde in PBS pH 7.4, and the samples were proc-
essed for transmission electron microscopy following
routine procedures (Masuelli et al. 2003).
In vivo treatment of BALB/c mice with GOS
BALB/c mice were subcutaneously injected in the right
flank with a 0.2ml suspension containing 1 106
SALTO cells in phosphate-buffered saline (PBS).
Groups of BALB/c mice (five mice per GOS-group
and seven mice per control (CTR)-group) were treated
weekly, starting three weeks after SALTO transplant-
ation, with an intratumoral injection of 15mg/kg of
GOS administered with corn oil (50ll) as vehicle for
two weeks and then with oral administration of
15mg/kg of GOS administered with corn oil (50ll)
three times a week. The control group (CTR) was
treated with corn oil employing the same protocol of
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GOS. Mice were sacrificed at the first signs of distress.
All experiments were approved by the Institutional
Animal Care and Use Committee (IACUC) and car-
ried out according to Italian rules (D.L.vo 116/92; CE.
609/86). The work was conducted with the formal
approval of the local human subject or animal care
committees (institutional and national), and the ani-
mal experiments have been registered as legislation
requires (Authorization from Ministry of Health n
187/2016-PR). A veterinary surgeon was present dur-
ing the experiments. Animal care, before and after the
experiments, was carried out only by trained person-
nel. Mice were bred under pathogen-free conditions in
the animal facilities of Tor Vergata University and
handled in compliance with European Union and
institutional standards for animal research (Masuelli
et al. 2010, 2014b).
Analysis of antitumor activity in vivo
Tumor growth was monitored weekly until tumor-
bearing mice were sacrificed at the first signs of dis-
tress or when their tumors exceeded 20mm in width
(Masuelli et al. 2016). Tumors were measured with a
caliper in two dimensions, and the volumes were cal-
culated by using the following formula: (width2 
length)/2 (Bei et al. 1998).
Statistical analysis
Data distribution of cell survival and the FACS analyses
were preliminarily verified by Kolmogorov–Smirnov
test, and data sets were analyzed by one-way analysis of
variance (ANOVA) followed by Newman–Keuls test.
Differences in the intensity of immunoreactive bands
were evaluated by a two-tailed Student’s t-test. Values
with p .05 were considered significant. Survival
curves and tumor volumes were estimated using the
Kaplan–Meier method and compared with a log-rank
test (Mantel-Cox). Differences in tumor volumes were
regarded as significant when the p value was .05
(Masuelli et al. 2010).
Results
Inhibition of human and mouse HNC cell survival
by GOS
The survival of tongue (CAL-27), pharynx (FaDu),
and salivary gland (A-253) carcinoma cell lines was
evaluated by the SRB assay after exposure to increas-
ing concentrations (1.25 lM, 2.5 lM, 5 lM, 10 lM,
20 lM, 40 lM, and 80 lM) of GOS or vehicle control
(DMSO), for 24 h, 48 h, and 72 h. Experiments were
also performed employing SALTO cells to establish
whether this mouse cancer cell line was susceptible to
the in vitro antitumor activity of GOS and would thus
be suitable for determining the in vivo antitumor
effects of GOS following SALTO cells transplantation
into BALB/c mice.
The effect of GOS on cell proliferation was dose-
and time-dependent and was significant compared to
the control at doses from 5 to 80 lM in FaDu, CAL-
27, and A-253 cell lines after 48 h (p< .001) and 72 h
(p< .001). After 24 h, GOS significantly decreased cell
survival at doses from 10 to 80 lM in FaDu, CAL-27,
and A-253 cells (p< .001) and at 5lM in CAL-27 and
A-253 cell lines (p< .05). GOS significantly reduced
SALTO cell survival at 20, 40, and 80 lM after 24
(p< .05 at 20 lM; p< .001 at 40–80 lM), 48 (p< .001)
and 72 h (p< .001) and at 10 lM only after 72 h of
treatment (p< .05). The mean results of three inde-
pendent experiments are reported in Figure 1.
The concentration of compound that inhibits 50%
of cell growth (IC50) was also determined. The con-
centrations of GOS required to reduce cell survival by
50% after 48 and 72 h were 9.74 and 4.75lM for
FaDu, respectively; 12.72 and 5.02 lM for CAL-27,
respectively; 18.56 and 6.57lM for A-253, respectively;
87.05 and 23.27lM for SALTO cells, respectively
(Table 1).
Effect of GOS on cell cycle distribution in HNC cell
lines
To evaluate the effect of GOS on cell cycle distribu-
tion, FACS analysis of DNA content was performed
on HNC cell lines treated with increasing doses of
GOS (5–40 lM) for 48 h. DMSO was used as the
vehicle control.
GOS treatment at the highest doses (20–40 lM)
increased the percentage of SALTO cells in the sub-
G1 phase and exerted the same effect on human CAL-
27 and A-253 cells at 10–20–40 lM and on FaDu cells
at all doses tested. The increase in the percentage of
cells in sub-G1 phase was associated with a decrease
in the percentage of cells in G0/G1, S, and G2/M
phases in FaDu, CAL-27, and A-253 cells and with a
reduction in the percentage of cells in S and G2/M
phases in SALTO cells. The mean results of three
independent experiments are reported in Table 2.
GOS mediates apoptosis in HNC cells
To corroborate the effect of GOS in mediating apop-
tosis, as seen by the GOS-mediated increase of the
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percentage of cells in sub-G1 phase, the expression
and activation of different signal transduction mole-
cules involved in the apoptotic process were evaluated
by Western blotting (Figure 2). HNC cell lines were
treated with 20 lM GOS or DMSO for 24 (FaDu,
CAL-27, and A-253) or 48 h (SALTO). After incuba-
tion, cell lysates were resolved in 10–12% SDS-PAGE,
transferred to nitrocellulose membranes and incubated
with specific antibodies.
GOS increased the Bax/Bcl-2 expression ratio com-
pared to controls (FaDu: p¼ .003; CAL-27: p¼ .003;
A-253: p¼ .007) and decreased the Bcl-2 levels in all
human HNC cells (FaDu: p¼ .002; CAL-27: p¼ .006;
A-253: p¼ .002).
In addition, a decreased p53 expression was
observed in FaDu (p¼ .007) and CAL-27 (p¼ .003)
cells after GOS treatment. A-253 were shown to lack
p53 (Reiss et al. 1992; Courtois et al. 1997).
In order to determine which apoptotic pathway
was activated after GOS treatment, the expression and
cleavage of procaspases 9, 8, and 3 were analyzed by
Western blotting in human HNC cell lines (Figure 2,
panel A). Treatment with GOS induced a significant
decrease of procaspase 9 expression level in FaDu
(p¼ .007), CAL-27 (p¼ .002) and A-253 (p¼ .003) cells.
In addition, GOS induced the proteolytic cleavage of
procaspase 9 into the active fragments in FaDu and
CAL-27, as indicated by the appearance of the active
fragments of 37, 35 kD. These results indicate the activa-
tion of the intrinsic pathway of apoptosis by GOS in
human HNC cell lines. In addition, GOS was able to
induce activation of the extrinsic pathway of apoptosis,
as demonstrated by the proteolytic cleavage of caspase 8
into the active fragments p43/41 in human HNC cell
lines.
Activated caspases 8 and 9 are able to cleave and
activate caspase 3, that induces the proteolytic inacti-
vation of PARP-1, a DNA repair enzyme. Our results
showed that GOS mediated the proteolytic cleavage of
caspase 3 into the activated fragments p19 and p17 in
FaDu, CAL-27, and A-253 cells. In addition, PARP-1
GOS-mediated proteolytic cleavage was observed in
human HNC cell lines (FaDu: p¼ .002; CAL-27:
p¼ .005; A-253: p¼ .002). Activation of apoptosis was
also demonstrated in SALTO cells by GOS-mediated
cleavage of caspase 3 and increase of the Bax/Bcl-2
ratio (p¼ .011) (Figure 2, panel B).
GOS activates the autophagic flux in HNC cells
The formation of an autophagosome is the marker of
autophagy. The activation of the autophagic process
can be detected by the conversion of light chain 3
(LC3)-I in LC3-II, because the amount of LC3-II
Table 1. GOS concentrations required for 50% inhibition of
HNC cell lines survival (IC50).
HNC cell lines GOS treatment (hours) IC50 (lM) ± SD
FaDu 48 9.74 ± 0.32
72 4.75 ± 0.08
CAL-27 48 12.72 ± 0.57
72 5.02 ± 0.13
A-253 48 18.56 ± 0.54
72 6.57 ± 0.64
SALTO 48 87.05 ± 9.22
72 23.27 ± 1.16
Figure 1. Effect of GOS on HNC cell lines survival. The survival of human (FaDu, CAL-27, A-253) and mouse (SALTO) HNC cell lines
were assessed by the SRB assay after 24, 48, and 72 h of treatment with DMSO or GOS. The percentage of surviving cells treated
with GOS or the vehicle control was calculated by normalizing the O.D. (Optical Density) value to that of the untreated control cul-
tures. The results are expressed as the means ± SD of three independent experiments performed in triplicate (p .05, #p .001
compared with the cultures treated with DMSO).
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correlates with the number of autophagosomes
(Mizushima & Yoshimori 2007). To evaluate the effect
of GOS on the induction of the autophagic flux, HNC
cells were treated with GOS (20lM) or DMSO for
24 (FaDu, CAL-27, and A-253) or 48 h (SALTO)
(Figure 3, panel A). Our results showed that GOS
induced the conversion of LC3-I into LC3-II, as dem-
onstrated by the significant increase in the amount of
LC3-II (FaDu: p¼ .0004; CAL-27: p¼ .006; A-253:
p¼ .005; SALTO: p¼ .017) and the significant
decrease of LC3-I expression (FaDu: p¼ .002; CAL-27:
p¼ .005; A-253: p¼ .0009) in GOS-treated cells com-
pared to DMSO-treated cultures.
To further investigate the mechanism of autophagy
induced by GOS, we evaluated the expression of
Beclin-1, because GOS is a BH3-mimetic compound
which is able to interrupt the interaction between Bcl-
2 and Beclin-1, thus activating Beclin-1-dependent
autophagy (Marquez & Liang 2012). Our results
showed that GOS significantly increased the expres-
sion of Beclin-1 in CAL-27 (p¼ .001), A-253
(p¼ .0008), and SALTO (p¼ .0002) cells, while the
expression of Beclin-1 did not change after GOS treat-
ment in FaDu cells.
The induction of the autophagic flux was con-
firmed employing transmission electron microscopy
using the CAL-27 cell line (Barth et al. 2010). CAL-27
cells were treated with GOS at the concentration of
10 lM for 24 h or with DMSO. No autophagic
vacuoles were seen in DMSO-treated cells. Conversely,
GOS-treated cells showed the presence of cytoplas-
matic autophagic vacuoles surrounded by double
membrane and containing cytoplasm and organelles
(Figure 3, panel B).
These results indicated that GOS was able to induce
activation of the autophagic flux in HNC cells.
GOS impairs the expression and activation of pro-
survival signaling pathway molecules in HNC cells
Different signaling transduction pathways are
involved in cell growth, autophagy, and apoptosis.
Abnormal expression and activation of ErbB recep-
tors and downstream signaling pathways are impli-
cated in the development and progression of head
and neck cancer (Bei et al. 2001; Sacco & Worden
2016). To evaluate whether GOS alters the expression
of EGFR/ErbB2 and the expression and activation of
extracellular signal-regulated kinases (ERK1/2), c-Jun
NH2-terminal kinases (JNK1/2), and p38-MAPKs
(p38-MAPKa) (Wada & Penninger 2004), Western
blotting analysis was performed after treating cells
with GOS (20 lM) or DMSO for 24 (FaDu, CAL-27
and A-253) or 48 h (SALTO). GOS treatment signifi-
cantly reduced EGFR expression compared to
DMSO-treated cells in FaDu cells (p¼ .002), while
GOS treatment did not change EGFR expression in
the other cell lines. Conversely, all GOS-treated cell
lines showed a reduced expression of ErbB2 com-
pared to DMSO-treated cells (p¼ .008 for FaDu;
p¼ .048 for CAL-27; p¼ .013 for A-253 and SALTO
cells) (Figure 4).
The levels of phosphorylated ERK1 (p-ERK1) and
ERK2 (p-ERK2) proteins, as well as p-p38-MAPKa
Table 2. Effects of GOS on cell cycle distribution. FACS analysis of DNA content was performed on asynchronized log phase grow-
ing HNC cells treated for 48 h with DMSO or GOS.
lM sub-G1a p Value G0/G1 p Value S p Value G2/M p Value
FaDu DMSO 2.83 ± 0.10 54.16 ± 1.65 10.52 ± 0.25 32.99 ± 1.75
GOS 5 14.79 ± 3.15 <.01 57.40 ± 3.10 NS 11.11 ± 0.17 NS 17.66 ± 0.11 <.001
GOS 10 25.98 ± 1.77 <.001 53.81 ± 0.25 NS 9.79 ± 0.17 NS 11.42 ± 2.11 <.001
GOS 20 53.04 ± 1.98 <.001 36.81 ± 1.20 <.001 6.75 ± 0.28 <.001 4.33 ± 0.58 <.001
GOS 40 77.84 ± 3.96 <.001 16.71 ± 1.99 <.001 2.00 ± 0.92 <.001 3.78 ± 1.12 <.001
CAL-27 DMSO 2.66 ± 0.16 59.95 ± 1.65 14.73 ± 0.26 23.03 ± 2.03
GOS 5 5.97 ± 3.36 NS 62.50 ± 4.24 NS 12.67 ± 1.68 NS 19.27 ± 5.93 NS
GOS 10 17.33 ± 2.23 <.05 60.19 ± 4.71 NS 13.45 ± 0.37 NS 9.47 ± 2.26 <.05
GOS 20 76.89 ± 1.99 <.001 22.01 ± 0.54 <.001 0.87 ± 0.54 <.001 0.79 ± 0.82 <.01
GOS 40 76.40 ± 7.16 <.001 17.83 ± 5.03 <.001 3.37 ± 1.03 <.001 2.69 ± 1.01 <.01
A-253 DMSO 11.65 ± 0.18 57.68 ± 1.35 11.35 ± 0.37 19.78 ± 0.76
GOS 5 15.42 ± 0.25 NS 53.75 ± 2.61 NS 11.37 ± 1.10 NS 19.82 ± 1.92 NS
GOS 10 19.67 ± 1.49 <.05 53.17 ± 4.14 NS 12.11 ± 2.01 NS 15.41 ± 0.59 <.05
GOS 20 41.49 ± 0.52 <.001 42.57 ± 0.28 <.01 7.87 ± 0.18 <.05 8.55 ± 1.00 <.001
GOS 40 77.00 ± 4.36 <.001 17.39 ± 3.01 <.001 2.73 ± 0.52 <.01 3.07 ± 0.87 <.001
SALTO DMSO 3.76 ± 0.49 36.49 ± 1.62 7.11 ± 0.46 52.95 ± 0.60
GOS 5 3.60 ± 0.57 NS 37.99 ± 1.38 NS 7.34 ± 0.52 NS 51.40 ± 1.23 NS
GOS 10 3.21 ± 0.41 NS 37.87 ± 0.33 NS 7.12 ± 0.52 NS 52.09 ± 0.45 NS
GOS 20 6.92 ± 0.55 <.05 39.83 ± 0.96 NS 5.74 ± 0.76 NS 47.33 ± 0.01 <.01
GOS 40 42.43 ± 1.84 <.001 39.34 ± 0.17 NS 4.03 ± 1.07 <.05 14.47 ± 0.72 <.001
aPercentage of cells in the sub-G1, G0/G1, S, and G2/M phases were calculated using Cell Quest software. The results are expressed as the means ± SD of
three independent experiments performed in triplicate. GOS was used in the range 5–40 lM. Statistical significance of the effects obtained with GOS was
calculated versus those obtained in DMSO-treated cells. NS: not significant.
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protein and p-JNK1 and p-JNK2 proteins, were com-
pared with the total ERK, p38, and JNK1/2 protein
levels, respectively. Our results showed that GOS sig-
nificantly decreased ERK1 and ERK2 phosphorylation
in FaDu (p-ERK1: p¼ .0002; p-ERK2: p¼ .0001),
CAL-27 (p-ERK1: p¼ .0009; p-ERK2: p¼ .027), A-253
(p-ERK1: p¼ .001; p-ERK2: p< .001), and SALTO (p-
ERK1: p¼ .0007; p-ERK2: p< .001) cells. GOS signifi-
cantly increased p38-MAPKa phosphorylation in all
cell lines (p¼ .004 for FaDu; p¼ .0002 for CAL-27;
p¼ .002 for A-253; p¼ .003 for SALTO cells). In add-
ition, GOS-treated FaDu, CAL-27, and A-253 cells
showed an increased expression of phosphorylated
JNK1 and JNK2 (FaDu: p¼ .001 for p-JNK1 and
p-JNK2; CAL-27: p¼ .04 for p-JNK1, p¼ .03 for
p-JNK2; A-253: p¼ .002 for JNK1, p¼ .001 for JNK2).
Conversely, GOS did not modify the expression of
p-JNK1/2 in SALTO cells (Figure 4).
Finally, we evaluated whether GOS treatment inhib-
ited the protein expression of the pro-survival kinase
AKT, which promotes tumor cells growth. GOS did
not alter the basal protein expression levels of AKT,
but significantly decreased the phosphorylated AKT
(p-AKT) protein levels compared with DMSO-treated
cells in FaDu (p¼ .016), CAL-27 (p¼ .001) and
SALTO (p¼ .007) cells. Conversely, in A-253 cells,
GOS significantly decreased only the basal protein
expression level of AKT (p¼ .019) (Figure 4).
Figure 2. Effect of GOS on molecules involved in apoptosis. Panel A: The expression of p53, Bax, Bcl-2, procaspases (9-8), cleaved
caspases (9-8-3), and PARP-1 cleavage was assessed by Western blotting in human HNC cell lines treated with GOS (20 lM) or
DMSO for 24 h. Panel B: The expression of Bax, Bcl-2, and cleaved caspase 3 was assessed by Western blotting in SALTO cell line
treated with GOS (20lM) or DMSO for 48 h. Actin was used as an internal control. The intensity of the bands obtained in two inde-
pendent experiments was quantified using ImageJ software after blot scanning, and the densitometric ratios between p53 and
actin, between Bax and Bcl-2, between Bcl-2 and actin, between procaspase 9 and actin, and between cleaved and full-length
PARP-1 are reported. n.d.: not detected.
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GOS reduces tumor growth in BALB/c mice
subcutaneously inoculated with SALTO cells
To evaluate the in vivo antitumor effect of GOS,
groups of BALB/c mice (five mice per GOS-group and
seven mice per CTR-group) were subcutaneously ino-
culated with 1 106 SALTO cells in the right flank.
These mice were treated by intratumoral injection
with GOS dissolved in corn oil (GOS) or with the
vehicle alone (corn oil, CTR), starting three weeks
after tumor cells transplant, one time a week for two
weeks. Then mice were treated with oral administra-
tion of GOS or corn oil three times a week.
GOS reduced the mean tumor volume compared to
control mice one week after the first GOS administra-
tion (75.9 versus 173.3mm3; p< .05) and maintained
this decrease until five weeks following the beginning
of treatment (676.0 versus 3565.7mm3; p< .0001)
(Figure 5, panel A). At this stage (eight weeks post-
transplant), the corn oil-treated mice were sacrificed
because of the excessive size of their tumors, while
all GOS-treated mice remained alive. Three GOS-
treated mice were sacrificed 9, 10, and 14 weeks post--
transplant, respectively. Two GOS-treated mice were
still alive after 16 weeks post-transplant, with a mean
tumor volume of 245.8mm3. GOS prolonged the
median survival time compared to corn oil (14 versus
8 weeks; p¼ .0009) (Figure 5, panel B). The risk of
SALTO tumor cell growth in the corn oil-treated group
was 43.44 relative to the GOS-treated group (Table 3).
Overall, our results indicated that GOS specifically
interfered with SALTO tumor cell growth.
Discussion
Polyphenols, a large group of phytochemicals ubiqui-
tously found in plants, exhibit antiinflammatory, anti-
microbial, anticancer, and immunomodulatory
Figure 3. Effect of GOS on the autophagic flux in HNC cells. Panel A: Assessment of the expression of Beclin-1, LC3-I, and LC3-II
with Western blotting in HNC cell lines treated with GOS (20lM) or DMSO for 24 or 48 h (SALTO). Actin was used as an internal
control. The intensity of the bands obtained in two independent experiments was quantified using ImageJ software after blot scan-
ning, and the densitometric ratios between Beclin-1 and actin, LC3-I and actin, LC3-II and actin are reported. n.d.¼ not detected.
Panel B: Ultrastructural analysis of autophagy on CAL-27 cells by transmission electron microscopy. CAL-27 cells were treated with
GOS at the concentration of 10lM for 24 h or with DMSO. N: Nucleus. Arrowheads indicate autophagic vacuoles surrounded by
double membrane. Original magnification 7900.
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activities, and thus are beneficial for human health
(Benvenuto et al. 2016).
Racemic Gossypol, ((±)-GOS; (±)-2,20-bis(8-Formyl-
1,6,7-trihydroxy-5-isopropyl-3-methylnaphthalene),
composed of both ()-GOS and (þ)-GOS, is the nat-
urally occurring polyphenol derived from cotton seeds
used in herbal medicines in China (Huang et al.
2006).
The purpose of our study was to evaluate the in
vitro and in vivo (±)-GOS antitumor activity in HNC
from different tumor sites (pharynx, tongue, and saliv-
ary gland).
To our knowledge, there is only one paper in which
the effect of (±)-GOS on HNC has been investigated
(Oliver et al. 2004). The authors compared the effects
of the racemic form and each of the enantiomers of
gossypol on cell survival of two squamous carcinoma
cell lines only (UM-SCC-6 and UM-SCC-14A). It was
reported that ()-GOS exhibited greater growth inhib-
ition than (±)-GOS, while (þ)-GOS had marginal
effect on cancer cells survival (Oliver et al. 2004).
Other papers have described the effect of ()-GOS
only as single agent or in combination with other
therapies employing squamous cell lines only from
HNC (Bauer et al. 2005; Wolter et al. 2006; Boehm
et al. 2008; Zerp et al. 2009; Imai et al. 2012; Lin et al.
2013b). Taking into account the small amount of
results available on the effects of (±)-GOS on HNC,
Figure 4. Effect of GOS on the expression and activation of ErbB receptors and pro-survival signaling pathway molecules. Western
blotting was performed on HNC cell lines that were treated with GOS (20 lM) or DMSO vehicle for 24 or 48 h (SALTO). The levels of
p-ERK1 and p-ERK2 proteins, as well as p-p38 protein, p-JNK1, and p-JNK2 proteins were compared with the total ERK, p38, and
JNK1/2 protein levels, respectively. The level of p-AKT was compared with the AKT protein level. Actin was used as an internal control.
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we sought to extensively investigate the anticancer
activity of (±)-GOS because it is the naturally occur-
ring polyphenolic yellow pigment found in cotton-
seed products. Conversely, ()-GOS is the levorota-
tory isomer of racemic gossypol resolved by various
HPLC (high-performance liquid chromatography)
methods (Hron et al. 1999).
Thus, the effects of (±)-GOS on the in vitro and in
vivo growth of head and neck cancer cell lines derived
from tumors arising from human pharynx (FaDu),
tongue (CAL-27), salivary gland (A-253), and from
Neu-overexpressing salivary adenocarcinoma arising
in BALB-neuT transgenic male mice (SALTO) and
those on signaling pathways aberrantly activated dur-
ing HNC progression were investigated.
We provide evidence that (±)-GOS inhibits the pro-
liferation of human HNC cell lines and murine
SALTO cells in a dose- and time-dependent manner.
Moreover, (±)-GOS treatment induced a dose-depend-
ent increase in the percentage of cells in the sub-G1
phase and thus induced the activation of apoptosis, as
confirmed by the increase of the Bax/Bcl-2 expression
ratio, caspase 3, and PARP-1 cleavages. In particular,
(±)-GOS activated both the intrinsic and extrinsic
apoptotic pathways in human HNC cell lines, as dem-
onstrated by the cleavage of procaspase 8 and 9.
Several studies have previously demonstrated that
gossypol is able to activate both the intrinsic and
extrinsic pathways of apoptosis in multiple myeloma
(Lin et al. 2013a), in human promyelocytic leukemia
cells (Hou et al. 2004), in human alveolar lung cancer
cells (Chang et al. 2004), and in human colon carcin-
oma (Wang et al. 2000; Zhang et al. 2003).
In addition, in the human HNC cell lines analyzed,
(±)-GOS treatment reduced the expression of p53.
Accordingly, p53, after the activation of the intrinsic
pathways of apoptosis, may be ubiquitinated and
degraded or the activation of apoptosis by (±)-GOS
might be due to a transcriptionally independent activ-
ities of p53 (Comel et al. 2014).
Beside inducing apoptosis, gossypol is also able to
induce autophagy. Previous studies have reported the
gossypol-induced activation of autophagy in prostate
cancer cells, HeLa cells, and breast adenocarcinoma
cells (Gao et al. 2010; Saleem et al. 2012). Our results
show that (±)-GOS decreases the Bcl-2 expression lev-
els in human HNC cell lines analyzed and thus make
Beclin-1 available to promote Beclin-1-dependent
autophagy. We also demonstrate that (±)-GOS induces
the activation of the autophagic flux in HNC cells, as
demonstrated by the increase of the amount of LC3-
II, by the significant decrease of LC3-I expression and
by the increase of the expression of Beclin-1 after
(±)-GOS treatment. Furthermore, we confirmed the
activation of autophagic flux in CAL-27 cells employ-
ing transmission electron microscopy.
Different signaling transduction pathways are
involved in cell growth, autophagy, and apoptosis.
Abnormal expression and activation of ErbB receptors
are implicated in the development and progression of
Table 3. Analysis of the survival of BALB/c mice after treatment with GOS by the log-rank test (Mantel-Cox).
95% hazard ratio confi-
dence limits
Variable Contrast Hazard ratio Lower Upper p Value Median survival (weeks)
Treatment GOS versus Corn Oil 43.44 4.677 403.5 0.0009 14 versus 8
Figure 5. GOS reduced tumor growth and increased the survival in BALB/c mice that were subcutaneously inoculated with SALTO
cells. Panel A: Differences in mean tumor volumes between BALB/c mice treated with GOS or corn oil (CTR). Panel B: Differences in
the mean survival duration of BALB/c mice treated with GOS or corn oil (CTR). The numbers of inoculated mice are reported in
“Materials and methods” section.
10 M. BENVENUTO ET AL.
head and neck cancer. Overexpression of ErbB family
receptors in the tumor is linked to poor outcome in
HNC patients (Sacco & Worden 2016). In our study,
we demonstrate that (±)-GOS is able to reduce both
EGFR and ErbB2 protein expression in HNC cell
lines.
Mitogen-activated protein kinases (MAPKs) consist
of three family members: extracellular signal-regulated
kinases (ERK1/2), c-Jun NH2-terminal kinases
(JNK1/2), and p38-MAPKs (p38-MAPKa) (Wada &
Penninger 2004). ERK1/2 MAPKs are activated in cells
following growth stimuli and are the intracellular
effectors of ErbB receptors. Hyperactivation of the
ERK1/2 signaling pathway frequently occurs in human
cancer and is associated with increased cell survival
and proliferation (Roberts & Der 2007). A previous
study showed that gossypol is able to inhibit the phos-
phorylation of ERK1/2 in multiple myeloma cells
(Sadahira et al. 2014). Accordingly, we demonstrate
that (±)-GOS is able to inhibit ERK1/2 phosphoryl-
ation in human and murine HNC cell lines. JNK1/2
and p38-MAPKa are activated in cells following stress
signals and are involved in the regulation of cell pro-
liferation, differentiation, and apoptosis (Wada &
Penninger 2004). A previous study has shown that
activation of the JNK pathway by ()-GOS is essential
for the induction of apoptosis in human leukemic cells
and head and neck squamous cell carcinoma (Zerp
et al. 2009). In addition, another study reported that
JNK activation mediates induction of autophagy in
head and neck squamous cell carcinoma (Li &
Johnson 2012). Our results are in agreement with
these previous findings. Indeed, we demonstrate that
(±)-GOS induces JNK1/2 phosphorylation in human
HNC cells, which probably mediates activation of
apoptosis and autophagy. Furthermore, it has been
shown that p38-MAPK activation is required for
TRAIL-induced apoptosis in HNC FaDu cells and for
FasL-related apoptosis in oral squamous cancer cells
(Kim et al. 2015; Park et al. 2015). Here, we demon-
strate that (±)-GOS is able to increase p38-MAPKa in
all HNC cell lines analyzed. Therefore, our data sug-
gest that (±)-GOS induction of apoptosis is likely
mediated by the activation of JNK1/2 and p38-
MAPKa in HNC cells.
Gossypol also inhibited the phosphorylation and
activation of the pro-survival kinase AKT, which
induces tumor growth. Previous studies showed that
gossypol, employed as single agent and also in
combination with valproic acid, was able to inhibit
the expression of AKT and phospho-AKT in
human prostate cancer cells (Jiang et al. 2009;
Zhao et al. 2015).
Several in vivo studies demonstrated that gossypol
possesses antitumoral activity in different types of can-
cer. Ko et al. showed that an intraperitoneal injection
of gossypol or gossypol acetic acid (GAA) (5–10mg/
kg) significantly reduced the growth of colorectal car-
cinoma induced by a subcutaneous injection of
COLO205 cells in nude mice (Ko et al. 2007).
Moreover, a recent study demonstrated the in vivo
antitumoral activity of orally ()-GOS (20–40mg/kg)
in a mouse model of medulloblastoma (Wang et al.
2015). Several in vivo studies investigated the activity
of gossypol in prostate cancer xenograft model in
nude mice. A study showed that orally ()-GOS
(10mg/kg) enhanced the antitumor activity of X-ray
irradiation leading to tumor regression and that oral
administration of gossypol was safety without side
effects in animals (Xu et al. 2005). Zhang et al.
reported that the daily intraperitoneal injection of
()-GOS (5–10mg/kg) for seven days significantly
inhibited tumor growth (Zhang et al. 2010).
Intralesional injection of ()-GOS (15mg/kg/d) in the
same murine model resulted in suppression of tumor
growth (Pang et al. 2011). However, at high doses
racemic GOS was shown to be toxic. Indeed, a toxicity
study was conducted employing racemic gossypol at
an orally dose of 120lmol/kg daily for five days, for
up to three weeks in BALB/c female mice (twice the
tolerated gossypol dose). Racemic GOS, at this dose,
induced weight loss, hepatotoxicity (increased levels
of ALT, AST, and regions of hepatocellular necrosis),
lymphopenia, and gastrointestinal toxicity (distension
of intestines, partial paralitic ileus, diffuse mucosal
damage, and necrosis) (Kitada et al. 2008). In add-
ition, gossypol has been shown to cause toxicity and
decreases fertility rates in ruminants and nonrumi-
nants that ingest it in high concentrations or over a
long time (Santana et al. 2015). Toxicity of gossypol
derives from the two aldehydic groups of its mol-
ecule. However, gossypol represents a potential start-
ing point for the development of antitumor drugs for
its anti-proliferative and antitumoral activities. Thus,
in order to use gossypol as anticancer drug, some
methods have been provided to synthesize gossypol
derivatives with reduced toxicity but with the same
biological activities (Wang et al. 2009; Yin et al.
2011). Toward this end, gossypol Schiff bases, gossy-
pol ethers, apogossypol series derivatives, gossypo-
lone, gossypol indane, halogenated gossypol,
periacetylated gossylic nitriles, periacetylated gossylic
imino-lactones, azo-derivatives, hydrazones, and thio-
derivatives of gossypol have been developed. In add-
ition, glycosilation of gossypol can increase the
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solubility and absorption in a biological system (Yin
et al. 2011).
Few papers investigated the in vivo effect of
()-GOS in murine models of HNC, and none of
these evaluated the in vivo effect of (±)-GOS.
()-GOS (5–15mg/kg, daily) was able to suppress
head and neck squamous cell carcinoma growth
employing an orthotopic xenograft mouse model of
aggressive human HNC with high Bcl-xL expression.
Gossypol was administered intraperitoneally as a sin-
gle agent and resulted well tolerated by animals
(Wolter et al. 2006). Imai et al. showed that oral
administration of ()-GOS (10mg/kg, daily for seven
days) in combination with taxotere increased survival
of mice bearing head and neck squamous cell carcin-
oma xenografts (Imai et al. 2012).
Given these observations, we evaluated the in vivo
effects of racemic GOS treatment in hampering the
growth of transplanted Neu-overexpressing BALB-
neuT salivary gland adenocarcinoma cells (SALTO) in
BALB/c mice. Racemic GOS has been intratumorally
administered for the first time in a syngeneic mouse
model of adenocarcinoma of HNC, i.e. adenocarcin-
oma of the salivary gland. (±)-GOS was intratumorally
administered in mice three weeks after a SALTO
tumor cell challenge one time a week for two weeks
and then mice were treated with oral administration
of (±)-GOS three times a week in order to maintain
an effective dose of (±)-GOS in mice. On the other
hand, the intratumoral route of administration should
make the compound directly available at the tumor
site, allowing for the highest concentration close to
tumor cells. Our results demonstrated that (±)-GOS
was able to significantly delay tumor growth and to
prolong median survival in agreement with our in
vitro observations. Mice treated with (±)-GOS showed
a significant decrease in the mean tumor volume com-
pared with control mice one week and until five weeks
after the first (±)-GOS administration and a prolonged
median survival time compared to corn oil-treated
mice (14 versus 8 weeks; p¼ .0009). Considering the
survival of BALB/c mice, the risk of SALTO tumor
cell growth in the corn oil-treated group was 43.44
relative to the (±)-GOS-treated group. Thus, our
results indicated that (±)-GOS specifically interfered
with SALTO tumor cell growth.
Taken together, our results indicate that the treat-
ment of HNC cells with (±)-GOS may be useful in the
inhibition of in vivo and in vitro cancer cell growth.
Therefore, the development of therapies targeting
Bcl-2 with BH-3 mimetics, as gossypol, could be a
promising strategy to enhance the antitumor efficacy
of existing standard regimens for HNC patients. The
principal metabolites of gossypol naturally occurring
after oral administration of racemic gossypol (gossy-
polone, gossypolonic acid, demethylated gossic acid,
and apogossypol) were identified in swine (Abou-
Donia & Dieckert 1975). For some of them (i.e. gossy-
polone), anticancer activity has been demonstrated in
vitro (Shelley et al. 1999; Dao et al. 2000). However,
further studies are needed to identify the in vivo
gossypol secondary metabolites which own anticancer
effects and to determine the best concentration of
gossypol to be in vivo administered for reaching the
effective dose.
Conclusions
Overall, we provided evidence that racemic gossypol
inhibits cell proliferation and induces apoptosis and
autophagy of human and mouse head and neck can-
cer cell lines. In addition, (±)-GOS possesses in vivo
antitumor activity, as demonstrated by its ability to
interfere with the growth of transplanted mouse sal-
ivary gland cancer cells in BALB/c mice. These find-
ings support further studies on the therapeutic
potential of gossypol, as anticancer drug, in combin-
ation with standard therapies in head and neck can-
cer patients.
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